Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
21
datasets available to search
ShareScore release 0.9.0
Dataset results
21 results for “antibody characterization”
In vivo characterization of antibodies directed against TREAT-AD target proteins in mouse model of AD pathology
<p><em>In vivo </em>characterization of antibodies directed against TREAT-AD target proteins (Moesin, CD44, Midkine, and SFRP1) in the 5xFAD mouse model</p>
Dataset Associated with "Biochemical and biophysical characterization of natural polyreactivity in antibodies"
<p>Processed data for recreating figures and statistical analysis from Borowska & Boughter et al. <em>Cell Reports</em> 2023. Scripts for creating the figures and analysis from these data, as well as the scripts used to generate these datasets, can be found on the GitHub page (https://github.com/ctboughter/manuscript_md_analysis)</p>
Characterization of Anti-FGFR3 Antibodies
ClinicalTrials.gov study NCT02539329. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Non Neutralizing Antibodies: Prevalence and Characterization
ClinicalTrials.gov study NCT01541527. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Introduction: Prompted by recent amendments of Yellow Fever (YF) vaccination guidelines from boost to single vaccination strategy and the paucity of clinical data to support this adjustment, we used the profile of the YF-specific CD8+ T-cell subset profiles after primary vaccination and neutralizing antibodies as a proxy for potentially longer lasting immunity. Methods and Findings: PBMCs and serum were collected in six individuals on days 0, 3, 5, 12, 28 and 180, and in 99 individuals >10 years after YF-vaccination. Phenotypic characteristics of YF- tetramer+ CD8+ T-cells were determined using class I tetramers. Antibody responses were measured using a standardized plaque reduction neutralization test (PRNT). Also, characteristics of YF-tetramer positive CD8+ T-cells were compared between individuals who had received a primary- and a booster vaccination. YF-tetramer+ CD8+ T-cells were detectable on day 12 (median tetramer+ cells as percentage of CD8+ T-cells 0.2%, range 0.07–3.1%). On day 180, these cells were still present (median 0.06%, range 0.02–0.78%). The phenotype of YF-tetramer positive CD8+ T-cells shifted from acute phase effector cells on day 12, to late differentiated or effector memory phenotype (CD45RA-/+CD27-) on day 28. Two subsets of YF-tetramer positive T-cells (CD45RA+CD27- and CD45RA+CD27+) persisted until day 180. Within all phenotypic subsets, the T-bet: Eomes ratio tended to be high on day 28 after vaccination and shifted towards predominant Eomes expression on day 180 (median 6.0 (day 28) vs. 2.2 (day 180) p = 0.0625), suggestive of imprinting compatible with long-lived memory properties. YF-tetramer positive CD8+ T-cells were detectable up to 18 years post vaccination, YF-specific antibodies were detectable up to 40 years after single vaccination. Booster vaccination did not increase titers of YF-specific antibodies (mean 12.5 vs. 13.1, p = 0.583), nor induce frequencies or alter phenotypes of YF-tetramer+ CD8+ T-cells. Conclusion: The presence of a functionally competent YF-specific memory T-cell pool 18 years and sufficient titers of neutralizing antibodies 35–40 years after first vaccination suggest that single vaccination may be sufficient to provide long-term immunity.
Dataset related to: Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis
<p><strong>Background/aim: </strong> Necrotizing crescentic glomerulonephritis (GN) associated with anti-neutrophil cytoplasmic antibodies (ANCA) against myeloperoxidase (MPO) is a devastating disease that quickly progresses to kidney failure. Current therapies are broadly immunosuppressive and associated with adverse effects. We wanted to set up a model that could be suitable for testing narrowly targeted therapies.</p> <p><strong>Methods: </strong> The model was constructed in male Wistar Kyoto rats through injections of human MPO (hMPO) and pertussis toxin, followed by a sub-nephritogenic dose of sheep anti-rat glomerular basement membrane (GBM) serum to boost the disease. Rats were monitored for 35 days. Rats given hMPO alone, saline, or human serum albumin with or without anti-GBM serum were also studied.</p> <p><strong>Results: </strong> Rats receiving hMPO developed circulating anti-hMPO and anti-rat MPO antibodies. Challenging hMPO-immunized rats with the anti-GBM serum led to more glomerular neutrophil infiltration and MPO release, and severe haematuria, heavy proteinuria, and higher blood urea nitrogen than hMPO alone. Pauci-immune GN developed with crescents, affecting 25% of glomeruli. The majority of crescents were fibrocellular. Necrotizing lesions and Bowman capsule ruptures were detected. Cells double positive for claudin-1 (a marker of parietal epithelial cells [PECs]) and neural cell adhesion molecule (NCAM; progenitor PECs) were present in crescents. Double staining for NCAM and Ki-67 established proliferative status of progenitor PECs. Podocyte damage was associated with endothelial and GBM changes by electron microscopy. Monocyte/macrophages and CD4+ and CD8+ T cells accumulated in glomeruli and the surrounding area and in the tubulointerstitium. Lung haemorrhage also manifested.</p> <p><strong>Conclusion: </strong> This model reflects histological lesions of human ANCA-associated rapidly progressive GN and may be useful for investigating new therapies.</p>
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Open the record for dataset details and reuse information.
Improving anti–CTLA-4 therapies through peptide masking and fragment crystallizable nonfucosylation: preclinical characterization of three novel antibodies
GEO Series GSE315417. Mus musculus. 105 samples. Type: Other.
Deep Characterization of the Human Antibody Response to Natural Infection Using Longitudinal Immune Repertoire Sequencing
GEO Series GSE123158. Homo sapiens. 210 samples. Type: Other.
SLE Antibody-Secreting Cells Are Characterized by Enhanced Peripheral Maturation and Survival Programs [RNA-seq]
GEO Series GSE235658. Homo sapiens. 58 samples. Type: Expression profiling by high throughput sequencing.
Monitoring Nivolumab binding as a method to clarify the residual therapeutic effects and to characterize the immune profile in antibody bound T cells in previously treated non-small cell lung cancer p
GEO Series GSE100860. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
Molecular characterization of chronic antibody mediated rejection in kidney transplantation (microRNA)
GEO Series GSE51676. Homo sapiens. 9 samples. Type: Non-coding RNA profiling by array.
Molecular characterization of chronic antibody mediated rejection in kidney transplantation (mRNA CD4)
GEO Series GSE64261. Homo sapiens. 10 samples. Type: Expression profiling by array.
Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development
ClinicalTrials.gov study NCT06718530. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis
ClinicalTrials.gov study NCT04700358. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
ClinicalTrials.gov study NCT05142540. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SLE Antibody-Secreting Cells Are Characterized by Enhanced Peripheral Maturation and Survival Programs [AIRR]
GEO Series GSE235659. Homo sapiens. 16 samples. Type: Other.
Molecular characterization of chronic antibody mediated rejection in kidney transplantation (mRNA)
GEO Series GSE51675. Homo sapiens. 18 samples. Type: Expression profiling by array.
Characterization of gene expression in antibody secreting cells
GEO Series GSE107683. Homo sapiens. 27 samples. Type: Expression profiling by array.
SLE Antibody-Secreting Cells Are Characterized by Enhanced Peripheral Maturation and Survival Program.
GEO Series GSE235660. Homo sapiens. 74 samples. Type: Expression profiling by high throughput sequencing; Other.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.